A joint Spanish and Israeli study, conducted by investigators from the Fundacion Jimenez Diaz University Hospital (IIS-FJD, UAM), Madrid, and the Israel Institute of Technology… Read More »Joint Spanish and Israeli research identifies recessive gene mutations underlying syndromic RP and intellectual disability
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 18th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »August 18th, 2017: “EURETINA-Brief”© Issue No. 159
Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has announced the submission of a Marketing Authorization Application (MAA) to the European Medicines… Read More »Spark Therapeutics files marketing authorization application at EMA for the treatment of Leber’s congenital amaurosis (LCA)
Results from a Phase II multicentre randomised trial, which had enrolled 67 patients, with macular telangiectasia 2, has reported meeting its primary endpoint, defined as… Read More »Phase II results from encapsulated cell therapy technology show benefit in the treatment of patients with macular telangiectasia 2
A US study, published in the journal Nature (Aug 3rd, 2017), has shown that a regenerative gene from zebrafish is capable of driving the generation… Read More »Reprogramming of Müller glia cells in mammalian retina promotes regeneration of neuronal cells following injury
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »August 4th, 2017: “EURETINA-Brief”© Issue No. 158.
Ocugen Inc., an ophthalmic biopharmaceutical company based in Pennsylvania, USA, has announced the close of a $7.5M venture capital funding to support the development of… Read More »Ophthalmic biopharmaceutical company raises $7.5M for the development of new treatments for sight-threatening disorders
Findings from a clinical research study published in the Lancet (Jul 13, 2017) show that patients with RPE-65 mediated retinopathy had a “statistically significant and… Read More »Phase III results of experimental gene therapy treatment for RPE-65 mediated retinal dystrophy report statistical and clinically meaningful benefit
A UK study, published in the American Journal of Respiratory Critical Care Medicine (Jun 8, 2017), indicates that patients with type 2 diabetes and obstructive… Read More »UK study indicates that type 2 diabetics with sleep apnoea appear to carry an increased risk of sight-threatening retinopathy
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the July 17th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »July 17th, 2017: “EURETINA-Brief”© Issue No. 157